Space News senior staff writer Jeff Foust contributed to this article from Washington. The chief executive had a closed one-on-one meeting May 17 with Axiom founder and CEO Kam Ghaffarian in Seoul.īoryung, along with Axiom and Starburst Aerospace, hosted the “Care in Space Challenge” this year, a collaborative space startup incubation program that awards winning entrepreneurs and their companies an equity investment of $100,000, and admission into Starburst’s 13-week accelerator program to help bring their ideas to fruition. The Boryung spokesperson said its space-related projects are all initiated and managed by a task force, called the Global Investment Center, which is under the direct control of CEO Jay Kim. Once docked, the Axiom Space astronauts plan to spend 10 days aboard the orbiting laboratory implementing a full mission comprised of science, outreach, and commercial activities. It reported 627.3 billion won ($488 million) in sales in 2021, up 11.6% year-on-year, with operating profit up 3.7% to 41.4 billion won. A SpaceX Falcon 9 rocket will launch the Ax-2 crew aboard a SpaceX Dragon spacecraft to the ISS from Launch Complex 39A at NASA’s Kennedy Space Center in Florida. Louis and prominent venture and family office investors.įounded in 1957 as a mom-and-pop pharmacy in Seoul, Boryung is now a major healthcare company in South Korea offering a range of medical and healthcare products and services. The company has since received investments from Mitsui & Co., Neventa Capital, Washington University of St. The company raised $130 million in Series B funds in early 2021 from Declaration Partners, C5 Capital, Prime Movers Labs and others. company “will close out toward the beginning of the new year.”Īxiom Space’s Series A investors included Hemisphere Ventures, The Venture Collective, Starbridge Venture Capital, Silicon Valley venture investors and super angels. Lee Young-hyeok, a Boryung spokesperson, told SpaceNews the company has a “strong commitment to exploring space-based healthcare solutions.”Īmir Blachman’ Axiom’s chief investment officer, said Boryung’s investment is “part of a larger funding round” that the U.S. “This strategic investment in Axiom will lay the foundation for finding diverse business opportunities in the private space industry,” Boryung said in a Dec. This follows Boryung’s $10 million investment in Axiom, disclosed in a May 16 regulatory filing, which gave the Korean company a 0.4% stake in the space station developer. 30 in exchange for the investment, according to the filing. 21 regulatory filing to the Financial Supervisory Service, calling the deal a “forward-looking investment” aimed at establishing a business footing in space.īoryung will take a 2.28% stake in Axiom by Dec. The Seoul-based company announced the decision in a Dec. commercial space station developer Axiom Space’s Series C funding round. SEOUL, South Korea - Boryung, a South Korean pharmaceutical company, has decided to invest $50 million in U.S.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |